**Core Concept**
Imatinib is a tyrosine kinase inhibitor used in the treatment of certain cancers, specifically chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It works by inhibiting specific tyrosine kinases involved in the signaling pathways of these cancers.

**Why the Correct Answer is Right**
Imatinib primarily acts on the BCR-ABL tyrosine kinase, which is a fusion protein resulting from the Philadelphia chromosome abnormality in CML. This abnormality arises from a translocation between chromosomes 9 and 22, leading to the fusion of the BCR and ABL genes. Imatinib binds to the ATP-binding site of the BCR-ABL tyrosine kinase, thereby inhibiting its activity and blocking the proliferation of cancer cells. This is a crucial mechanism in the treatment of CML.

**Why Each Wrong Option is Incorrect**
**Option A:** Imatinib does not primarily act on the HER2 tyrosine kinase, which is involved in the signaling of breast cancer cells.
**Option B:** Imatinib does not primarily act on the EGFR tyrosine kinase, which is involved in the signaling of various types of cancer cells.
**Option C:** Imatinib does not primarily act on the JAK tyrosine kinase, which is involved in the signaling of cytokine receptors.

**Clinical Pearl / High-Yield Fact**
When prescribing imatinib, it is essential to monitor patients for potential side effects such as gastrointestinal disturbances, rash, and fluid retention. Additionally, regular blood counts and liver function tests should be performed to monitor for signs of toxicity.

**Correct Answer: B. BCR-ABL tyrosine kinase.